Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2
This book aims to gather the current knowledge regarding different aspects of brain and spinal cord tumors in order to more efficiently help the patients. Brain tumors comprise about 5–9% of all human neoplasms; and the central nervous system (CNS) neoplasms are ranked among the most prevalent neoplasms of childhood as well. The more we know about the nature and characteristic of brain and spinal cord tumors, the more precise decision could be made for each patient, in order to reach the best outcome. While surgical resection, chemotherapy, and radiotherapy have been considered as the standards of care for benign and/or malignant CNS tumors since a long time ago, new therapeutic approaches...
Insights in Neuro-Oncology and Neurosurgical Oncology: 2021
We are now entering the third decade of the 21st Century, and, especially in the last years, the achievements made by scientists have been exceptional, leading to major advancements in the fast-growing field of Oncology. Frontiers has organized a series of Research Topics to highlight the latest advancements in research across the field of Oncology, with articles from the Associate Members of our accomplished Editorial Boards. This editorial initiative of particular relevance, led by Prof. David Eisenstat, Specialty Chief Editor of the Neuro-Oncology and Neurosurgical Oncology section, together with Prof. Erik Sulman, focused on new insights, novel developments, current challenges, latest di...
Novel Diagnostic and Therapeutic Strategies in the Management of Cerebral Gliomas
Cerebral gliomas account for 45% of all primary central nervous system (CNS) tumors. The median survival after the initial diagnosis of glioblastoma (GBM) is only 15 months, and less than 10% of patients survive three years post-diagnosis. Surgical treatment followed by adjuvant therapies such as radiotherapy and chemotherapy represents the classical strategy in glioma management. The revised WHO 2016 classification now distinguishes the oligodendrogliomas with 1p19q codeletion and IDH mutation from the astrocytomas with or without IDH mutations, thereby creating homogenous and pathologically distinct subgroups. While the status of gene expression and mutations define components of GBM subtypes, it was also found that response to therapies was different for each subtype, suggesting that personalized treatment based on genomic alterations could lead to a more favorable outcome for this disease.
